Literature DB >> 15168587

Chronic graft-versus-host disease: clinical features and grading systems.

Gérard Socié1.   

Abstract

Chronic graft-versus-host disease (GVHD) is the prime cause of transplantation-related mortality late after marrow grafting and contributes directly or indirectly to most nonmalignant complications. The main clinical symptoms and diagnostic problems of chronic GVHD are summarized here. A major issue in treating chronic GVHD is to assess disease severity. A critical review of published grading systems failed to demonstrate that any system is better than the others. Prospective validation of the Johns Hopkins grading scale is timely and warranted.

Entities:  

Mesh:

Year:  2004        PMID: 15168587     DOI: 10.1532/ijh97.03174

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

1.  Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.

Authors:  Gorgun Akpek; Stephanie J Lee; Mary E Flowers; Steven Z Pavletic; Mukta Arora; Shing Lee; Steven Piantadosi; Katherine A Guthrie; James C Lynch; Alessandra Takatu; Mary M Horowitz; Joseph H Antin; Daniel J Weisdorf; Paul J Martin; Georgia B Vogelsang
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

Review 2.  Nonmalignant late effects after allogeneic stem cell transplantation.

Authors:  Gérard Socié; Nina Salooja; Amnon Cohen; Attilio Rovelli; Enric Carreras; Anna Locasciulli; Elisabeth Korthof; Joachim Weis; Vincent Levy; André Tichelli
Journal:  Blood       Date:  2003-01-02       Impact factor: 22.113

Review 3.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Authors:  K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

4.  Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.

Authors:  G Socié; J V Stone; J R Wingard; D Weisdorf; P J Henslee-Downey; C Bredeson; J Y Cahn; J R Passweg; P A Rowlings; H C Schouten; H J Kolb; J P Klein
Journal:  N Engl J Med       Date:  1999-07-01       Impact factor: 91.245

5.  Systemic evaluation of Sjögren-like syndrome after bone marrow transplantation in man.

Authors:  A Janin-Mercier; A Devergie; J P Arrago; C Brocheriou; F Lemarchand-Venencie; J D Rain; E Gluckman
Journal:  Transplantation       Date:  1987-05       Impact factor: 4.939

Review 6.  How I treat chronic graft-versus-host disease.

Authors:  G B Vogelsang
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

7.  Development of a prognostic model for grading chronic graft-versus-host disease.

Authors:  G Akpek; M L Zahurak; S Piantadosi; J Margolis; J Doherty; R Davidson; G B Vogelsang
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

8.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

9.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  3 in total

1.  Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype.

Authors:  Philipp G Hemmati; Theis H Terwey; Gero Massenkeil; Philipp le Coutre; Lam G Vuong; Stefan Neuburger; Bernd Dörken; Renate Arnold
Journal:  Int J Hematol       Date:  2010-02-25       Impact factor: 2.490

2.  Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.

Authors:  Akiyoshi Takami; Kanako Mochizuki; Hirokazu Okumura; Satsuki Ito; Yukio Suga; Hirohito Yamazaki; Masahide Yamazaki; Yukio Kondo; Hidesaku Asakura; Shinji Nakao
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

3.  Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT).

Authors:  John E Levine; Bruce R Blazar; Todd DeFor; James L M Ferrara; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.